103 related articles for article (PubMed ID: 9315836)
21. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to infectious diseases society of america guidelines.
Orrick JJ; Segal R; Johns TE; Russell W; Wang F; Yin DD
Pharmacoeconomics; 2004; 22(11):751-7. PubMed ID: 15250752
[TBL] [Abstract][Full Text] [Related]
22. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
23. Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.
Oh HM; Ng AW; Lee SK
Singapore Med J; 1996 Jun; 37(3):255-7. PubMed ID: 8942221
[TBL] [Abstract][Full Text] [Related]
24. [Empirical antibacterial therapy of community acquired pneumonia in outpatients].
Yakovlev SV; Suvorova MP
Antibiot Khimioter; 1997; 42(10):23-8. PubMed ID: 9412399
[No Abstract] [Full Text] [Related]
25. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
[TBL] [Abstract][Full Text] [Related]
26. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.
Kuti JL; Capitano B; Nicolau DP
Pharmacoeconomics; 2002; 20(8):513-28. PubMed ID: 12109917
[TBL] [Abstract][Full Text] [Related]
27. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
Friedman H; Song X; Crespi S; Navaratnam P
Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
[TBL] [Abstract][Full Text] [Related]
28. Intravenous penicillin--still the first-line therapy for pediatric community-acquired pneumonia.
Korppi M
Pediatr Pulmonol; 2013 Apr; 48(4):408-9. PubMed ID: 22778061
[No Abstract] [Full Text] [Related]
29. Chloramphenicol versus ampicillin plus gentamicin for community acquired very severe pneumonia among children aged 2-59 months in low resource settings: multicentre randomised controlled trial (SPEAR study).
Asghar R; Banajeh S; Egas J; Hibberd P; Iqbal I; Katep-Bwalya M; Kundi Z; Law P; MacLeod W; Maulen-Radovan I; Mino G; Saha S; Sempertegui F; Simon J; Santosham M; Singhi S; Thea DM; Qazi S;
BMJ; 2008 Jan; 336(7635):80-4. PubMed ID: 18182412
[TBL] [Abstract][Full Text] [Related]
30. [Estimation of the clinical and pharmacoeconomic efficiency of treatment in patients with community-acquired pneumonia with third-generation cephalosporins].
Starodubtseva OI; Vakhrushev IaM
Probl Tuberk Bolezn Legk; 2009; (6):28-9. PubMed ID: 19642570
[TBL] [Abstract][Full Text] [Related]
31. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.
Carratalà J; Garcia-Vidal C; Ortega L; Fernández-Sabé N; Clemente M; Albero G; López M; Castellsagué X; Dorca J; Verdaguer R; Martínez-Montauti J; Manresa F; Gudiol F
Arch Intern Med; 2012 Jun; 172(12):922-8. PubMed ID: 22732747
[TBL] [Abstract][Full Text] [Related]
32. Antibiotic treatment of community acquired pneumonia in well-nourished young Nigerian children.
Ajayi MT; Oladokun RA; Falade AG
J Trop Pediatr; 2005 Oct; 51(5):319-20. PubMed ID: 15980026
[No Abstract] [Full Text] [Related]
33. The clinical relevance of in-vitro resistance to penicillin, ampicillin, amoxycillin and alternative agents, for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
Klugman KP
J Antimicrob Chemother; 1996 Jul; 38 Suppl A():133-40. PubMed ID: 8858479
[TBL] [Abstract][Full Text] [Related]
34. Containing costs and containing bugs: are they mutually exclusive?
Nicolau DP
J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S12-7. PubMed ID: 19236136
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ;
BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956
[TBL] [Abstract][Full Text] [Related]
36. Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US.
Paladino JA; Adelman MH; Schentag JJ; Iannini PB
Pharmacoeconomics; 2007; 25(8):677-83. PubMed ID: 17640109
[TBL] [Abstract][Full Text] [Related]
37. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
Welte T; Petermann W; Schürmann D; Bauer TT; Reimnitz P;
Clin Infect Dis; 2005 Dec; 41(12):1697-705. PubMed ID: 16288390
[TBL] [Abstract][Full Text] [Related]
38. A population-based study of the costs of care for community-acquired pneumonia.
Bartolomé M; Almirall J; Morera J; Pera G; Ortún V; Bassa J; Bolíbar I; Balanzó X; Verdaguer A;
Eur Respir J; 2004 Apr; 23(4):610-6. PubMed ID: 15083763
[TBL] [Abstract][Full Text] [Related]
39. [Impact of clinical practice guides on the cost of caring for community acquired pneumonia].
Boada Senciales F; Moreno Arrebola E; Buñuel Alvarez JC; Vila Pablos C
An Pediatr (Barc); 2008 Aug; 69(2):154-8. PubMed ID: 18755121
[TBL] [Abstract][Full Text] [Related]
40. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
